Vaxart Good Will vs Deferred Long Term Liab Analysis

VXRT Stock

USD 1.02 0.08 8.51%

Vaxart financial indicator trend analysis is much more than just breaking down Vaxart Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vaxart Inc is a good investment. Please check the relationship between Vaxart Good Will and its Deferred Long Term Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Good Will vs Deferred Long Term Liab

Good Will vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vaxart Inc Good Will account and Deferred Long Term Liab. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Vaxart's Good Will and Deferred Long Term Liab is 0.49. Overlapping area represents the amount of variation of Good Will that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Vaxart Inc, assuming nothing else is changed. The correlation between historical values of Vaxart's Good Will and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Good Will of Vaxart Inc are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Good Will i.e., Vaxart's Good Will and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

0.49

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Good Will

An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from Vaxart's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vaxart Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Enterprise Value is likely to gain to about 130.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 21.2 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	70.6M	110.4M	86.2M	44.6M
Cost Of Revenue	48.7M	3.3M	4.5M	4.3M

Total Operating Expenses Cost Of Revenue

Vaxart fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock Total Equity	Common Stock
Total Assets		0.53	0.1	0.45	0.98	0.57	-0.64	-0.53	0.82	0.68	0.39	0.9	-0.1	0.7	0.42	-0.18	0.58	0.73	0.65	0.48	0.85	0.27	0.09	0.04	-0.57	-0.41
Short Long Term Debt Total	0.53		0.0	0.3	0.4	0.94	0.24	-0.89	0.05	0.87	0.71	0.17	-0.34	0.95	0.55	0.12	0.78	0.88	0.69	0.91	0.06	0.89	0.12	-0.1	-0.75	-0.67
Other Current Liab	0.1	0.0		0.77	0.08	0.02	-0.04	0.04	0.05	-0.04	-0.17	0.02	0.68	-0.08	-0.35	-0.08	0.04	0.01	0.07	-0.04	0.08	-0.03	-0.36	-0.22	0.05	0.15
Total Current Liabilities	0.45	0.3	0.77		0.43	0.37	-0.19	-0.2	0.28	0.31	0.06	0.28	0.62	0.28	-0.24	-0.14	0.43	0.23	0.3	0.27	0.33	0.14	-0.2	0.22	-0.31	-0.23
Total Stockholder Equity	0.98	0.4	0.08	0.43		0.47	-0.73	-0.37	0.87	0.61	0.32	0.93	-0.01	0.6	0.26	-0.15	0.47	0.6	0.48	0.4	0.91	0.11	0.07	0.12	-0.54	-0.36
Property Plant And Equipment Net	0.57	0.94	0.02	0.37	0.47		0.16	-0.85	0.09	0.9	0.82	0.26	-0.31	0.92	0.49	0.21	0.77	0.85	0.68	0.87	0.19	0.72	0.07	0.02	-0.74	-0.66
Net Debt	-0.64	0.24	-0.04	-0.19	-0.73	0.16		-0.13	-0.95	0.0	0.28	-0.88	-0.13	0.0	-0.04	0.34	0.08	-0.09	-0.14	0.12	-0.91	0.34	-0.01	-0.1	0.01	-0.13
Retained Earnings	-0.53	-0.89	0.04	-0.2	-0.37	-0.85	-0.13		-0.13	-0.73	-0.6	-0.26	0.4	-0.85	-0.75	0.13	-0.71	-0.95	-0.84	-0.83	-0.15	-0.83	-0.01	0.25	0.51	0.44
Cash	0.82	0.05	0.05	0.28	0.87	0.09	-0.95	-0.13		0.24	-0.1	0.95	0.04	0.28	0.21	-0.33	0.17	0.35	0.36	0.13	0.94	-0.07	0.04	0.07	-0.22	-0.05
Non Current Assets Total	0.68	0.87	-0.04	0.31	0.61	0.9	0.0	-0.73	0.24		0.76	0.38	-0.32	0.92	0.5	0.09	0.66	0.83	0.66	0.8	0.31	0.61	0.41	-0.1	-0.82	-0.83
Non Currrent Assets Other	0.39	0.71	-0.17	0.06	0.32	0.82	0.28	-0.6	-0.1	0.76		0.16	-0.52	0.71	0.48	0.52	0.56	0.63	0.51	0.5	0.1	0.4	0.2	0.0	-0.6	-0.58
Cash And Short Term Investments	0.9	0.17	0.02	0.28	0.93	0.26	-0.88	-0.26	0.95	0.38	0.16		-0.08	0.4	0.32	-0.22	0.31	0.48	0.47	0.18	0.98	-0.07	0.0	0.08	-0.3	-0.11
Net Receivables	-0.1	-0.34	0.68	0.62	-0.01	-0.31	-0.13	0.4	0.04	-0.32	-0.52	-0.08		-0.41	-0.77	-0.25	-0.24	-0.41	-0.43	-0.25	0.05	-0.33	-0.39	0.24	0.27	0.3
Common Stock Shares Outstanding	0.7	0.95	-0.08	0.28	0.6	0.92	0.0	-0.85	0.28	0.92	0.71	0.4	-0.41		0.58	0.05	0.75	0.92	0.72	0.89	0.29	0.78	0.25	-0.11	-0.81	-0.75
Non Current Liabilities Total	0.42	0.55	-0.35	-0.24	0.26	0.49	-0.04	-0.75	0.21	0.5	0.48	0.32	-0.77	0.58		-0.09	0.42	0.75	0.86	0.42	0.18	0.55	0.28	-0.41	-0.26	-0.27
Inventory	-0.18	0.12	-0.08	-0.14	-0.15	0.21	0.34	0.13	-0.33	0.09	0.52	-0.22	-0.25	0.05	-0.09		-0.06	-0.1	-0.16	-0.05	-0.21	0.0	-0.1	0.21	-0.1	-0.03
Other Current Assets	0.58	0.78	0.04	0.43	0.47	0.77	0.08	-0.71	0.17	0.66	0.56	0.31	-0.24	0.75	0.42	-0.06		0.69	0.63	0.66	0.21	0.6	-0.03	0.18	-0.68	-0.53
Other Stockholder Equity	0.73	0.88	0.01	0.23	0.6	0.85	-0.09	-0.95	0.35	0.83	0.63	0.48	-0.41	0.92	0.75	-0.1	0.69		0.86	0.81	0.37	0.75	0.11	-0.32	-0.6	-0.51
Total Liab	0.65	0.69	0.07	0.3	0.48	0.68	-0.14	-0.84	0.36	0.66	0.51	0.47	-0.43	0.72	0.86	-0.16	0.63	0.86		0.56	0.35	0.61	0.17	-0.28	-0.41	-0.38
Property Plant And Equipment Gross	0.48	0.91	-0.04	0.27	0.4	0.87	0.12	-0.83	0.13	0.8	0.5	0.18	-0.25	0.89	0.42	-0.05	0.66	0.81	0.56		0.11	0.84	0.09	-0.08	-0.7	-0.63
Total Current Assets	0.85	0.06	0.08	0.33	0.91	0.19	-0.91	-0.15	0.94	0.31	0.1	0.98	0.05	0.29	0.18	-0.21	0.21	0.37	0.35	0.11		-0.19	-0.05	0.14	-0.24	-0.04
Short Term Debt	0.27	0.89	-0.03	0.14	0.11	0.72	0.34	-0.83	-0.07	0.61	0.4	-0.07	-0.33	0.78	0.55	0.0	0.6	0.75	0.61	0.84	-0.19		0.11	-0.25	-0.55	-0.49
Intangible Assets	0.09	0.12	-0.36	-0.2	0.07	0.07	-0.01	-0.01	0.04	0.41	0.2	0.0	-0.39	0.25	0.28	-0.1	-0.03	0.11	0.17	0.09	-0.05	0.11		-0.27	-0.41	-0.7
Accounts Payable	0.04	-0.1	-0.22	0.22	0.12	0.02	-0.1	0.25	0.07	-0.1	0.0	0.08	0.24	-0.11	-0.41	0.21	0.18	-0.32	-0.28	-0.08	0.14	-0.25	-0.27		-0.07	0.04
Common Stock Total Equity	-0.57	-0.75	0.05	-0.31	-0.54	-0.74	0.01	0.51	-0.22	-0.82	-0.6	-0.3	0.27	-0.81	-0.26	-0.1	-0.68	-0.6	-0.41	-0.7	-0.24	-0.55	-0.41	-0.07		0.82
Common Stock	-0.41	-0.67	0.15	-0.23	-0.36	-0.66	-0.13	0.44	-0.05	-0.83	-0.58	-0.11	0.3	-0.75	-0.27	-0.03	-0.53	-0.51	-0.38	-0.63	-0.04	-0.49	-0.7	0.04	0.82

Click cells to compare fundamentals

Vaxart Account Relationship Matchups

Vaxart fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	37.0M	152.6M	221.2M	153.8M	91.8M	150.6M
Short Long Term Debt Total	2.3M	7.2M	13.0M	21.7M	26.5M	28.4M
Other Current Liab	2.9M	3.4M	836K	8.2M	5.6M	9.6M
Total Current Liabilities	9.2M	11.8M	10.8M	17.9M	13.7M	17.6M
Total Stockholder Equity	13.0M	123.4M	187.5M	110.6M	57.8M	89.3M
Property Plant And Equipment Net	2.2M	8.3M	19.8M	41.3M	36.6M	27.5M
Net Debt	(11.2M)	(119.7M)	(130.7M)	(22.3M)	(8.2M)	(8.7M)
Retained Earnings	(116.7M)	(148.9M)	(219.4M)	(327.1M)	(409.6M)	(389.1M)
Cash	13.5M	126.9M	143.7M	44.0M	34.8M	52.2M
Non Current Assets Total	19.4M	24.1M	52.0M	54.4M	46.3M	40.4M
Non Currrent Assets Other	141K	372K	890K	3.6M	926K	879.7K
Cash And Short Term Investments	13.5M	126.9M	166.5M	93.7M	39.7M	61.2M
Net Receivables	3.6M	334K	71K	20K	3.0M	2.9M
Common Stock Shares Outstanding	21.6M	88.3M	121.5M	127.7M	144.8M	152.1M
Liabilities And Stockholders Equity	37.0M	152.6M	221.2M	153.8M	91.8M	150.6M
Non Current Liabilities Total	14.9M	17.4M	22.9M	25.3M	20.3M	27.5M
Other Current Assets	453K	1.3M	2.6M	3.7M	2.8M	4.6M
Other Stockholder Equity	129.6M	272.3M	406.9M	438.0M	467.4M	490.7M
Total Liab	24.1M	29.2M	33.6M	43.3M	34.0M	44.6M
Property Plant And Equipment Gross	2.2M	8.3M	19.8M	15.6M	43.4M	24.7M
Total Current Assets	17.6M	128.5M	169.2M	99.5M	45.5M	43.3M
Accumulated Other Comprehensive Income	(1.6M)	(459K)	(74K)	(299K)	(1K)	(1.1K)
Short Term Debt	841K	2.1M	1.0M	2.2M	6.5M	6.8M
Intangible Assets	17.1M	15.4M	10.6M	5.0M	4.3M	4.1M
Accounts Payable	852K	2.1M	3.9M	5.5M	1.6M	1.5M
Common Stock Total Equity	714K	4.8M	11K	13K	11.7K	11.1K
Common Stock	714K	5K	11K	13K	15K	14.3K
Current Deferred Revenue	4.6M	4.2M	5.1M	2M	1.8M	1.7M
Other Liab	13.4M	14.9M	10.9M	5.9M	6.7M	7.9M
Net Tangible Assets	13.0M	123.4M	187.5M	110.6M	127.2M	67.4M
Other Assets	141K	372K	890K	3.6M	4.1M	4.3M
Retained Earnings Total Equity	(116.7M)	(148.9M)	(219.4M)	(327.1M)	(294.4M)	(279.7M)
Capital Surpluse	124.8M	272.3M	406.9M	438.0M	503.7M	528.9M
Property Plant Equipment	210K	1.5M	6.6M	15.6M	17.9M	18.8M

Pair Trading with Vaxart

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vaxart position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxart will appreciate offsetting losses from the drop in the long position's value.

Moving together with Vaxart Stock

0.76

Equillium Earnings Call This Week

Pair Corr

Moving against Vaxart Stock

0.76

ELYM

Eliem Therapeutics

Pair Corr

The ability to find closely correlated positions to Vaxart could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vaxart when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vaxart - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vaxart Inc to buy it.

The correlation of Vaxart is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vaxart moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vaxart Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Vaxart can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Vaxart Inc is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Vaxart Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Vaxart Inc Stock. Highlighted below are key reports to facilitate an investment decision about Vaxart Inc Stock:

How To Invest In Vaxart

Details

Is Vaxart Stock a good investment?

Details

What is Vaxart's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Complementary Tools for Vaxart Stock analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.

	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	CEOs Directory Screen CEOs from public companies around the world
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios

Is Vaxart's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vaxart. If investors know Vaxart will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vaxart listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.57)

Revenue Per Share

0.051

Quarterly Revenue Growth

146.5

Return On Assets

(0.42)

Return On Equity

(0.98)

The market value of Vaxart Inc is measured differently than its book value, which is the value of Vaxart that is recorded on the company's balance sheet. Investors also form their own opinion of Vaxart's value that differs from its market value or its book value, called intrinsic value, which is Vaxart's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vaxart's market value can be influenced by many factors that don't directly affect Vaxart's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vaxart's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vaxart is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaxart's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vaxart Good Will vs Deferred Long Term Liab Analysis

Good Will vs Deferred Long Term Liab

Good Will vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Good Will

Deferred Long Term Liab

Vaxart fundamental ratios Correlations

Vaxart Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vaxart fundamental ratios Accounts

Pair Trading with Vaxart

Moving together with Vaxart Stock

Moving against Vaxart Stock

Complementary Tools for Vaxart Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Cash And Short Term Investments
Common Stock Shares Outstanding	+ 0.95	Short Long Term Debt Total
Cash And Short Term Investments	+ 0.95	Cash
Property Plant And Equipment Net	+ 0.94	Short Long Term Debt Total
Total Current Assets	+ 0.94	Cash

Other Stockholder Equity	- 0.95	Retained Earnings
Cash	- 0.95	Net Debt
Total Current Assets	- 0.91	Net Debt
Retained Earnings	- 0.89	Short Long Term Debt Total
Cash And Short Term Investments	- 0.88	Net Debt
Common Stock Shares Outstanding	- 0.85	Retained Earnings